T-WAVE is a new Phase 2 clinical study for patients with absence seizures. The study will evaluate whether an investigational oral drug is safe for adolescents and adults diagnosed with absence seizures. The study will explore if the drug is effective in decreasing the frequency and duration of seizures by reducing abnormal activity in certain regions of the brain.

All participants eligible for T-WAVE will receive the investigational oral drug.

Contact our study center to see if you qualify to participate in T-WAVE.

Learn more at www.TWAVEstudy.com

The safety and effectiveness of CX-8998 for treatment of epilepsy have not been established.

T-WAVE

Study Sponsor
Cavion



Have you or a loved one been diagnosed with absence seizures?

Consider joining this new clinical study

The T-WAVE clinical study will evaluate whether an investigational oral drug for adolescents and adults diagnosed with absence seizures is safe and investigate how the drug works. Researchers will also explore if the drug is effective in decreasing the frequency and duration of seizures by reducing abnormal activity in certain regions of the brain.

All participants eligible for T-WAVE will receive the investigational oral drug.

You or a loved one may be eligible for this study if you:

- ✓ Are 16-55 years old and not pregnant or breastfeeding
- ✓ Have been diagnosed with an idiopathic generalized epilepsy (IGE) such as childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, or Jeavons syndrome with absence seizures
- ✓ Are on a stable dose of antiepileptic medication for at least 30 days, or have documentation justifying lack of therapy
- ✓ Have no history of surgical intervention for the treatment of epilepsy

Participation in the study is free.

About T-WAVE

The T-WAVE clinical study will evaluate whether investigational oral drug CX-8998 is safe for adolescents and adults diagnosed with idiopathic generalized epilepsy (IGE) with absence seizures and explore whether it is safe. Researchers will also explore if the drug is effective in decreasing the frequency and duration of seizures by reducing abnormal activity in certain regions of the brain.

Participating in T-WAVE

The study is being conducted at several medical research centers in the United States. Participation may take up to nine weeks, including a four- week screening period, four-week treatment period and one week of follow-up. There will also be a follow up call about four weeks after your last dose to see how you are doing.

All participants eligible for T-WAVE will receive the investigational oral drug.

Study participation, testing and medication are all free to participants. Some people may receive stipends to cover meals and travel related to study visits.

Eligibility requirements for the T-WAVE Study include:

- Men and women (not pregnant or breastfeeding) 16-55 years old
- Diagnosis of an idiopathic generalized epilepsy (IGE) such as childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, or Jeavons syndrome with absence seizures
- On a stable dose of antiepileptic medication for at least 30 days, or documentation justifying lack of therapy
- Have no history of surgical intervention for the treatment of epilepsy

The safety and effectiveness of CX-8998 for treatment of epilepsy have not been established.

www.TWAVEstudy.com

About CX-8998

The brain's neural network utilizes certain channels, called T-type calcium channels, that help control communication between brain regions. Idiopathic generalized epilepsy (IGE) with absence seizures is associated with abnormal activity of these signals. CX-8998 is an oral drug that was designed to selectively target T-type calcium channel activity in the brain's neurons, acting as a biological "pacemaker" to help restore the brain's natural rhythms. Scientific data suggest that CX-8998 may reduce seizures by suppressing abnormal T-type calcium channel activity and restoring normal neural activity in relevant brain regions.

CX-8998 has been studied in nearly 250 people, mostly healthy volunteers and people with tremor and other neurological conditions. CX-8998 is being developed by Cavion, Inc., a patient-focused company advancing T-type calcium channel therapies for a range of neurological diseases.

The safety and effectiveness of CX-8998 for treatment of epilepsy have not been established.